Current Report Filing (8-k)
November 06 2020 - 4:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 6, 2020
CELLDEX THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
000-15006
|
|
13-3191702
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
Perryville III Building, 53 Frontage
Road, Suite 220,
Hampton, New Jersey 08827
(Address of principal executive offices)
(Zip Code)
(908) 200-7500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common Stock, par value $.001
|
CLDX
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
Previously, on May 19, 2016, Celldex
Therapeutics, Inc. (the “Company”) entered into a Controlled Equity OfferingSM Sales Agreement
(the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), as sales agent, pursuant to which
the Company may offer and sell, from time to time, through Cantor shares of its common stock, par value $0.001 per share. On November
6, 2020, the Company filed a prospectus registering the offer and sale of shares of common stock of up to an additional $50.0
million pursuant to the Sales Agreement.
The Company is not obligated to sell any
shares under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, Cantor will use commercially reasonable
efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and
the rules of the Nasdaq Capital Market to sell shares from time to time based upon the Company’s instructions, including
any price, time or size limits specified by the Company. Under the Sales Agreement, Cantor may sell shares by any method deemed
to be an “at the market offering” as defined in Rule 415(a)(4) under the U.S. Securities Act of 1933, as
amended, or any other method permitted by law. Cantor’s obligations to sell shares under the Sales Agreement are subject
to satisfaction of certain conditions, including customary closing conditions. The Company will pay Cantor a commission equal to
3.0% of the aggregate gross proceeds from each sale of shares and has agreed to provide Cantor with customary indemnification and
contribution rights. The Company has also agreed to reimburse Cantor for certain specified expenses.
Sales of shares of common stock under
the Sales Agreement will be made pursuant to the registration statement on Form S-3ASR (File No. 333-249917), which
became effective upon filing with the U.S. Securities and Exchange Commission (the “SEC”), and a related
prospectus filed with the SEC on November 6, 2020 for an aggregate offering price of up to an additional $50.0 million.
As
previously disclosed, on June 12, 2020, the Company filed a prospectus supplement (the “June 12 Prospectus
Supplement”) registering the offer and sale of shares of common stock of up to $75.0 million pursuant to the Sales
Agreement, and on June 15, 2020, the Company filed a supplement to the June 12 Prospectus Supplement (the “June 15
Supplement”) to reduce the remaining amount of common stock being offered thereunder to $18.25 million. After June 12,
2020 and through November 5, 2020, the Company has issued 1,554,351 shares of its common stock pursuant to the Sales
Agreement for aggregate gross proceeds of approximately $12.5 million. The Company does not intend to effect any further
sales under the June 12 Prospectus Supplement or the June 15 Supplement and is currently only offering to sell shares of its
common stock in an aggregate amount of $50.0 million pursuant to the Sales Agreement.
The foregoing summary of the Sales Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, which is
included as Exhibit 1.1 hereto.
This Current Report on Form 8-K shall
not constitute an offer to sell or the solicitation of an offer to buy any shares under the Sales Agreement, nor shall there be
any sale of such shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.
Item 9.01 Financial Statements and Exhibits.
(d)
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELLDEX THERAPEUTICS, INC.
|
|
|
Date: November 6, 2020
|
By:
|
/s/ Sam Martin
|
|
|
Sam Martin
|
|
|
Title: Senior Vice President and Chief Financial Officer
|
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2023 to Apr 2024